Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32
Biodesix, Inc.
Biodesix, Inc. BDSX | 0.00 |
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:
BDSX) with a Buy rating and announces Price Target of $32.
